Dublin biotech Nuritas has become a founding industry residency partner of the University of Limerick's iBio degree, an integrated BSc and MSc in Immersive Bioscience and Biotherapeutics, Silicon Republic reported on 10 November 2026. Nuritas gains access to the programme's first student cohort and will work with UL educators on how the course develops.
iBio students spend about half of their time on paid residencies in industry and graduate with a master's degree in four years. Eli Lilly and Analog Devices were the partners named when UL launched the programme in May 2025.
- What happened: Nuritas joins UL's iBio programme as a founding industry residency partner (Silicon Republic, 10 November 2026).
- The degree: integrated BSc and MSc, completed in four years, with up to two years of paid industry experience.
- Other partners: Eli Lilly and Analog Devices, named at the programme launch on 29 May 2025.
- First intake: September 2026, according to UL.
- Number of residency places at Nuritas, duration and funding: not disclosed.
- Nuritas: founded in Dublin in 2014; uses AI and molecular biology to find bioactive peptides for consumer health ingredients.
What does the Nuritas and UL partnership involve?
According to Silicon Republic, Nuritas will host iBio students as a founding industry residency partner. The company gets early access to the programme's first cohort, and its scientists will work with UL educators so that the course reflects what the sector needs. Neither UL nor Nuritas had published a press release on its own website when we checked on 12 November 2026, and the number of students Nuritas will take, the length of each residency and any payment between the parties were not disclosed.
Dr Nora Khaldi, founder and chief executive of Nuritas, told Silicon Republic: "We recognised the same innovative and disruptive mindset at iBio that drives our work at Nuritas." Professor Jakki Cooney, iBio's course co-founder, said the degree was built to change how students learn the science of making and discovering medicines, and that it aims to show students both the scientific problems and the commercial realities of the industry.
How does the iBio degree work?
iBio was developed by UL's Department of Biological Sciences in the Faculty of Science and Engineering, with input from the biopharma industry. Instead of lecture-based teaching, the programme's website describes interactive workshops and laboratory sessions in which teams work on industry problems using real biotech data. Students keep a working-week schedule of 9am to 5pm, Monday to Friday, and study across three semesters a year.
| Item | Detail |
|---|---|
| Award | Integrated BSc and MSc in Immersive Bioscience and Biotherapeutics |
| Length | Four years, three semesters per year |
| Residencies | About half of students' time; paid; starting in Year 1 |
| Industry experience at graduation | Up to two years, across three companies |
| First intake | September 2026 |
| Industry partners named by UL | Eli Lilly and Company, Analog Devices (ADI) |
| Industry partner announced in November 2026 | Nuritas |
| Cohort size | Not disclosed |
UL launched the programme on 29 May 2025 at its Bernal Institute, with James Lawless TD, Minister for Further and Higher Education, Research, Innovation and Science. At that launch UL said further biopharma partners were expected to join. Professor Cooney, then described as iBio course director, said: "At iBio, we are committed to cultivating the leading scientific minds of the future."
Who is Nuritas?
Nuritas was founded in Dublin in 2014 by Dr Nora Khaldi, who holds a PhD in molecular evolution and bioinformatics. The company says it uses artificial intelligence, through a platform it calls Magnifier, together with molecular biology to discover bioactive peptides in natural sources and then tests them in clinical studies. It is based in a research facility in Dublin.
Its ingredient brands include PeptiStrong, PeptiSleep and PeptiYouth. Nuritas says its peptides are used in more than 100 products worldwide and that it holds 56 issued patents. In August 2026 it announced a peer-reviewed PeptiSleep study in the journal Sleep Medicine: X, and in September 2026 it appointed Kees Kruythoff, a former president of Unilever North America, as board chair. Its website lists Enterprise Ireland among its partners and backers. Nuritas does not publish staff numbers or recent funding totals on its site.
Why does the partnership matter for Irish life sciences?
The iBio model places students inside companies for a large part of their degree, so the mix of host companies shapes what graduates learn. Until now the named hosts were Eli Lilly, which makes medicines in Limerick and Kinsale, and Analog Devices, whose ADI Catalyst centre hosted an iBio industry day in January 2026. Nuritas adds an Irish-founded company working on AI-led discovery and nutrition science, which gives students exposure to a smaller, research-driven business as well as large multinational plants.
For Nuritas, the arrangement offers an early link to students who have trained in bioscience and biotherapeutics since their first year. For UL, it widens the range of residency hosts for a programme whose first intake was set for September 2026. Neither side has published a target for how many iBio graduates it expects Nuritas to hire.
Frequently asked questions
What is the iBio programme at UL?
It is a four-year integrated BSc and MSc in Immersive Bioscience and Biotherapeutics at the University of Limerick, in which students spend about half their time on paid industry residencies.
What will Nuritas do in the iBio programme?
Nuritas is a founding industry residency partner. It will host students and work with UL educators on the programme. The number of places has not been disclosed.
Which other companies are iBio partners?
UL has named Eli Lilly and Company and Analog Devices. UL said at the launch that more biopharma partners were expected.
When did iBio start taking students?
UL said the first intake would be in September 2026.
Is the iBio residency paid?
Yes. UL says the industry residencies are paid. Pay rates have not been published.
Outlook
The next points to watch are whether more Irish biotech companies join as residency hosts, how many students the programme admits in its second intake, and when the first cohort begins work at Nuritas. Priya Life Science will update this report if UL or Nuritas publishes further detail. More on the university is on our University of Limerick page.
Sources
- Silicon Republic, Irish biotech Nuritas to partner with UL to develop next-gen of scientists, 10 November 2026
- University of Limerick, iBio programme launch at the University of Limerick, 29 May 2025
- University of Limerick, Immersive Bioscience and Biotherapeutics (iBio) programme website, accessed 12 November 2026
- Nuritas, About Nuritas, accessed 12 November 2026
- Nuritas, Nuritas Published Peer-Reviewed PeptiSleep Sleep Study in Sleep Medicine: X, 11 August 2026
- Nuritas, Nuritas Appoints Former Unilever North America President Kees Kruythoff as Board Chair, 10 September 2026
Cover image: the Living Bridge over the River Shannon at the University of Limerick campus, June 2015. Photo: William Murphy, CC BY-SA 2.0, via Wikimedia Commons, cropped.